Background: Endothelial dysfunction has been documented in patients with type 2 diabetes especially when combined with hypertension. We prospectively investigated the effects of pioglitazone in improving endothelial function in hypertensive type 2 diabetic patients during the 6-month follow-up. Methods: Hypertensive type 2 diabetic patients were randomly assigned to pioglitazone (n = 25) or placebo (n = 25). Primary endpoint was to compare changes in brachial artery flow-mediated dilation (baFMD) between the 2 groups during the 6-month follow-up. Secondary endpoints were to compare respectively) were significantly greater in the pioglitazone group when compared to the placebo group during the 6-month follow-up. No significant differences in the prevalences of new onset heart failure, fracture, and bladder cancer were noted during the follow-up between the 2 groups. Decreases in the levels of inflammatory marker such as IL-6 (-2.54 ± 2.32 pg/mL vs. -1.34 ± 2.12 pg/mL, p 0.05, respectively), TNF-(-1.54 ± 1.51 pg/mL vs. 0.14 ± 1.12 pg/mL, p 0.05, α ＜ ＜ respectively), sICAM-1 (-39 ± 52 ng/mL vs. 6 ± 72 ng/mL, p 0.05, respectively), and sVCAM-1 (-154 ± 198 ng/mL vs. ＜ -11 ± 356 ng/mL, p 0.05, respectively) were significantly greater in the pioglitazone group compared to the placebo ＜ group during the follow-up. Conclusions: In hypertensive type 2 diabetic patients, pioglitazone may increase baFMD and circulatory microRNA-21 and decrease inflammatory cytokines including IL-6, TNF-, sICAM-1, and sVCAM-1. 
Introduction been more frequently documented in type 2 diabetic patients when combined with hypertension. 1, 2) Hypertension is as an independent predictor for coronary heart disease, congestive heart failure, stroke, renal failure, and ischemic target vessel revascularization. 3, 4) Hypertension often accompanies carbohydrate and lipid abnormalities as part of the metabolic syndrome, 5) and patients with the metabolic syndrome are at higher risk of cardiovascular morbidity and mortality. 5) Hypertension when combined with diabetes increase the risk of cardiovascular events. [6] [7] [8] Several studies highlight the beneficial effect of pioglitazone in reducing coronary atherosclerosis in type 2 diabetic patients. 7, 9) However, the US Food and Drug
Administration has informed the public that use of the pioglitazone for more than 1 year may be associated with an increased risk of bladder cancer especially for men. 10, 11) A meta-analysis suggests that the pioglitazone confers excess risk for fractures especially for women. 12, 13) Although anecdotal adverse events with pioglitazone have been reported, these findings have not been shown in large prospective, randomized studies. In our previous study, early decreases in the number of natural killer cells, circulating tumor necrosis factor-(TNF-), inter α α -leukin-6 (IL-6), and monocyte chemoattractant protein-1 concentration, and the expression of chemokine receptor 2 on circulating CD14+ cells have been noted after pioglitazone treatment, subsequently reducing atherosclerosis progression in type 2 diabetic patients. 7) The early decreases in smooth muscle cell migration and proliferation in the pioglitazone group have been observed in type 2 diabetic patients. MicroRNAs are post-transcriptional regulators that bind to complementary sequences on target mRNAs. 14) The human genome may encode > 1,000
microRNAs and target about 60% of mammalian genes. 14) Aberrant expression of microRNAs implicated in numerous disease states. We prospectively investigated the effects of pioglitazone in improving endothelial function, the changes in microRNA-17, -21, -92a, -126, -145, and the correlation between the changes in brachial artery flow-mediated dilation (baFMD) and microRNAs in hypertensive type 2 diabetic patients during the 6-month follow-up.
Subjects and methods
Study patients
Patients were eligible for this study if they were 45 to 
Blood pressure measurements
Blood pressure was measured using mercury sphygmomanometer (WA Baum Co., Inc., Copiague, NY, USA) after 10 minutes of resting in a quiet room in the sitting position, and any medications or caffeine-containing drinks which may influence the blood pressure were not taken within 12 hours prior to the blood pressure measurement.
A large cuff was used if the circumference of the arm was > 32 cm. SiDBP, SiSBP, and pulse rate were measured by a single investigator. Phase I and V Korotkoff sounds from the brachial artery were used as a systolic and a diastolic pressure, respectively. Heart rate was measured for one minute before blood pressure was measured.
Measurements of brachial artery flow-mediated dilation
Patients fasted for at least 8 h before the flow-mediated dilation (FMD) study; moreover, patients were educated not to exercise and not to ingest substances that might affect FMD such as caffeine, high-fat foods and vitamin C or use tobacco for at least 4 hour before the study. 
Measurement of inflammatory markers
Inflammatory markers such as hsCRP, IL-6, TNF-, α adiponectin, sICAM-1, and sVCAM-1 were measured in both groups at the beginning of the study and at 6-month follow-up. Venous blood samples were drawn from each patient after eight hours or overnight fasting. Blood samples were centrifuged to obtain plasma, and the plasma was stored at -80°C. TNF-was measured by a sandwich α enzyme linked immuno sorbent assay (ELISA) with a minimum detectable level of 0.5 pg/mL (ALPCO Diagnostics, Salem, NH, USA). Undetectable TNF-val α -ues were recorded as 0.4 pg/mL for one patient. IL-6 was also measured by a sandwich ELISA with a minimum detectable level of 0.16 pg/mL (ALPCO Diagnostics).
The hsCRP concentrations were quantified using a latex nephelometer II (Dade Behring Inc., Newark, DE, USA).
Plasma adiponectin concentration was assessed by radioimmunoassay (Linco Research Inc., St. Charles, MO, USA). The sensitivity of this assay was 0.78 ng/mL. The coefficients of variation for intra-and inter-assay were 9.3% and 15.3%, respectively. In addition, sICAM-1 and sVCAM-1 were measured using a commercially available 
Results

Study patients
Baseline patient characteristics of the pioglitazone group (n = 25) and the control group (n = 25) were not different ( Table 1 Fig. 2A, B) . Changes in the expressions of microRNA-17, -92a, -126, -145) did not show significant differences between the 2 groups during the 6-month follow-up (Fig. 2C ).
Changes in inflammatory markers and lipid profiles
Decreases in inflammatory markers such as IL-6 (-2.54 ± 2.32 pg/mL vs. -1.34 ± 2.12 pg/mL, p 0.05, ＜ respectively), TNF-(-1.54 ± 1.51 pg/mL vs. 0.14 ± 1.12 α pg/mL, p 0.05, respectively), sICAM-1 (-39 ± 52 ng/mL ＜ vs. 6 ± 72 ng/mL, p 0.05, respectively), and sVCAM-1 ＜ (-154 ± 198 ng/mL vs. -11 ± 356 ng/mL, p 0.05, re ＜ -spectively) were significantly greater in the pioglitazone group when compared to the control group during the 6-month follow-up (Table 3) . Moreover, significant increases in adiponectin concentrations were found in the pioglitazone group when compared to the control group (1.47 ± 0.89 g/mL vs. 0.98 ± 0.88 g/mL, p 0.05, μ μ ＜ respectively). However, no significant changes in hsCRP concentrations were noted between the 2 groups.
Moreover, levels of total cholesterol and low density lipoprotein (LDL) cholesterol decreased significantly in both groups when compared to the baseline during the 6-month follow-up; however, changes from baseline showed no significant differences between the 2 groups (Table 4 ). (Table 5 ).
Clinical follow-up
Discussion
Hypertensive type 2 diabetic patients are more prone to endothelial dysfunction, leading to atherosclerosis progression. 15) A diabetic medication which also improves endothelial dysfunction can be of significant clinical benefit to diabetic patients especially when combined The purpose of this prospective, randomized, single-blinded, investigator-initiated, 6-month follow-up study was to compare the effects of pioglitazone on brachial artery endothelial function, inflammatory markers, and circulating microRNAs in hypertensive type 2 diabetic patients.
This is the first prospective, randomized study to dem- Changes from baseline (pg/mL) -1.54 ± 1.51 † 0.14 ± 1.12
High MicroRNA-21 is known to play critical parts in the pathogenesis of cardiac cell growth and death, smooth muscle cell proliferation and apoptosis, and cardiac fibroblast activation. 19, 20) Expression of microRNA-21 is deregulated in arteries and cardiomyocytes in patients with cardiovascular diseases such as cardiac hypertrophy, congestive heart failure, and ischemic heart disease. 
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